P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates
- 18 September 2018
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 6 (11) , 3063-3074
Abstract
P-glycoprotein (Pgp) has been considered as a major cause of cancer multidrug resistance; however, clinical solutions to overcome this drug resistance do not exist despite the tremendous endeavors. The lack of cancer specificity is a main reason for clinical failure of conventional approaches. Targeted photodynamic therapy (PDT) is highly cancer specific by combining antibody targeting and locoregional light irradiation. We aimed to develop Pgp-targeted PDT using antibody–photosensitizer conjugates made of a recombinant Fab fragment. We prepared the photosensitizer conjugates by expressing a recombinant Fab fragment and specifically linking IR700-maleimide at the C-terminal of the Fab heavy chain. In vitro studies showed that the Fab conjugates specifically bind to Pgp. Their phototoxicity was comparable to full antibody conjugates when assayed with conventional 2-D cell culture, but they outperformed the full antibody conjugates in a 3-D tumor spheroid model. In a mouse xenograft model of chemoresistant tumors, Fab conjugates showed Pgp specific delivery to chemoresistant tumors. Upon irradiation with near-infrared light, they caused rapid tumor shrinkage and significantly prolonged the survival of tumor-bearing mice. Compared to the full antibody conjugates, Fab conjugates took a shorter time to reach peak tumor levels and achieved a more homogeneous tumor distribution. This allows light irradiation to be initiated at a shorter time interval after the conjugate injection, and thus may facilitate clinical translation. We conclude that our targeted PDT approach provides a highly cancer-specific approach to combat chemoresistant tumors, and that the conjugates made of recombinant antibody fragments are superior to full antibody conjugates for targeted PDT.Keywords
Funding Information
- National Institutes of Health (R01CA194064)
- National Institutes of Health (R01EB014354)
- National Institutes of Health (NCI CCSG P30CA012197)
This publication has 38 references indexed in Scilit:
- P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumorsJournal of Controlled Release, 2018
- EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancerJournal of Controlled Release, 2016
- Dendritic nanoconjugates of photosensitizer for targeted photodynamic therapyActa Biomaterialia, 2015
- Assessments of antibody biodistributionThe Journal of Clinical Pharmacology, 2015
- Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotidesBiomaterials, 2013
- Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacyJournal of Controlled Release, 2012
- Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?Cancer and Metastasis Reviews, 2012
- Recent trends in antibody-based oncologic imagingCancer Letters, 2012
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearanceAdvanced Drug Delivery Reviews, 2008
- Multicell tumor spheroids in photodynamic therapyLasers in Surgery and Medicine, 2006